Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Shares Purchased by KBC Group NV

KBC Group NV lifted its holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 30.5% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 2,615 shares of the biopharmaceutical company’s stock after buying an additional 611 shares during the quarter. KBC Group NV’s holdings in Agios Pharmaceuticals were worth $86,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of the business. State Street Corp raised its stake in Agios Pharmaceuticals by 10.2% during the third quarter. State Street Corp now owns 2,331,433 shares of the biopharmaceutical company’s stock worth $103,586,000 after acquiring an additional 216,484 shares during the period. Erste Asset Management GmbH acquired a new position in Agios Pharmaceuticals in the third quarter valued at approximately $97,199,000. Geode Capital Management LLC raised its position in shares of Agios Pharmaceuticals by 0.5% during the 3rd quarter. Geode Capital Management LLC now owns 1,357,531 shares of the biopharmaceutical company’s stock worth $60,326,000 after purchasing an additional 6,101 shares during the period. Frazier Life Sciences Management L.P. raised its position in shares of Agios Pharmaceuticals by 19.7% during the 3rd quarter. Frazier Life Sciences Management L.P. now owns 1,044,154 shares of the biopharmaceutical company’s stock worth $46,392,000 after purchasing an additional 172,180 shares during the period. Finally, Fisher Asset Management LLC lifted its holdings in shares of Agios Pharmaceuticals by 20.5% in the 3rd quarter. Fisher Asset Management LLC now owns 855,328 shares of the biopharmaceutical company’s stock worth $38,002,000 after purchasing an additional 145,416 shares during the last quarter.

Insider Activity

In other news, insider Tsveta Milanova sold 2,804 shares of the firm’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $32.18, for a total transaction of $90,232.72. Following the completion of the transaction, the insider now owns 18,906 shares in the company, valued at approximately $608,395.08. This trade represents a 12.92 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 4.93% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on AGIO. StockNews.com upgraded Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, November 9th. Scotiabank upped their price target on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a “sector outperform” rating in a research report on Monday, December 9th. Cantor Fitzgerald reissued an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Wednesday, December 18th. Finally, Royal Bank of Canada raised their price target on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an “outperform” rating in a research note on Tuesday, December 10th. Five investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, Agios Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $56.33.

Agios Pharmaceuticals Price Performance

Shares of NASDAQ:AGIO opened at $33.46 on Monday. The stock has a market cap of $1.91 billion, a price-to-earnings ratio of 2.95 and a beta of 0.88. Agios Pharmaceuticals, Inc. has a 12 month low of $23.70 and a 12 month high of $62.58. The stock’s 50 day moving average price is $37.83 and its 200 day moving average price is $43.86.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.